EUVIMEDEUVIMED entdecken
Crossref

The Impact of Tumor Immune Microenvironment in EGFR-Mutant Non-Small Cell Lung Cancer on the Efficacy of Osimertinib

Megumi Mizutani, Yoshiya Matsumoto, Chisato Ohe, Akira Sugimoto, Hiroaki Nagamine, Yoko Tani, Takako Oka, Hiroyasu Kaneda, Kazuhiro Yamada, Tetsuya Watanabe, Kazuhisa Asai, Tatsuo Kimura und 3 weitere

Clinical Lung Cancer · 2026-11 · 27 (9) · 1-10

DOI: 10.1016/j.cllc.2026.09.003 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Lung Cancer, 2026-11. Verfasst von Megumi Mizutani und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory Medicine, Graduate School of Medicine, Osaka Metropolitan University, Osaka, Japan. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Aniline Compounds, Lung Neoplasms, Acrylamides. Die Arbeit nennt 45 Literaturangaben. Gefördert von: Japan Society for the Promotion of Science.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: The relationship between the tumor microenvironment, comprising programmed cell death-1 ligand-1 (PD-L1), CD8-positive tumor-infiltrating lymphocytes (CD8+TIL), and FOXP3+TIL, in patients with epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC) and its clinicopathological features and the efficacy of EGFR-tyrosine kinase inhibitors remain poorly understood. METHODS: Patients treated with osimertinib or afatinib as first-line treatment were included. PD-L1 (clone: 22C3) expression was classified as positive or negative; CD8+TIL and FOXP3+TIL expressions were assessed via immunohistochemistry, and categorized as high or low. Thereafter, tumor immune microenvironment (TIME) was categorized into 4 classes according to PD-L1 and CD8+TIL statuses: class 1, positive/high; class 2, negative/low; class 3, positive/low; and class 4, negative/high. RESULTS: Among the TIME classes, there were no significant correlations with clinicopathological factors. Progression-free survival (PFS) with osimertinib differed according to the TIME classification (median PFS: 7.6 vs. 17.7 vs. 14.8 vs. 34.0 months for classes 1-4, respectively; P = .0019). PFS was significantly shorter in the FOXP3+TIL-high group than in the low group (median PFS: 8.3 vs. 18.1 months, P = .031). Multivariable analysis showed that high FOXP3+TIL status was independently associated with shorter PFS (HR 2.28, P = .019); class 4 TIME was independently associated with longer PFS (HR 0.28, P = .004). CONCLUSION: The TIME classification based on PD-L1 and CD8+TIL statuses, as well as FOXP3+TIL status, may help predict the efficacy of osimertinib in EGFR-mutant NSCLC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungAniline CompoundsLung NeoplasmsAcrylamidesTumor MicroenvironmentHumansIndolesPyrimidinesFemaleErbB ReceptorsMaleMutationAgedMiddle AgedLymphocytes, Tumor-InfiltratingProtein Kinase InhibitorsB7-H1 AntigenPrognosisRetrospective Studies

Stichwörter der Autor:innen

Epidermal growth factor receptorProgrammed cell death-1 ligand-1

Substanzen

osimertinibIndolesPyrimidinesAniline CompoundsAcrylamidesErbB ReceptorsEGFR protein, humanProtein Kinase InhibitorsB7-H1 Antigen

Autor:innen und Institutionen

  • Department of Respiratory Medicine, Graduate School of Medicine, Osaka Metropolitan University, Osaka, Japan.
  • Department of Respiratory Medicine, Graduate School of Medicine, Osaka Metropolitan University, Osaka, Japan. Electronic address: yoshi_matsumoto@omu.ac.jp.
  • Department of Surgical Pathology, Hyogo Medical University School of Medicine, Nishinomiya, Japan; Department of Pathology, Graduate School of Medicine, Osaka Metropolitan University, Osaka, Japan.
  • Department of Clinical Oncology, Graduate School of Medicine, Osaka Metropolitan University, Osaka, Japan.
  • Department of Premier Preventive, Graduate School of Medicine, Osaka Metropolitan University, Osaka, Japan.
  • Department of Pathology, Graduate School of Medicine, Osaka Metropolitan University, Osaka, Japan.

Förderung

  • Japan Society for the Promotion of Science

Zitieren

APA

Mizutani, M., Matsumoto, Y., Ohe, C., Sugimoto, A., Nagamine, H., Tani, Y., Oka, T., Kaneda, H., Yamada, K., Watanabe, T., Asai, K., Kimura, T., Shiohara, M., Kohashi, K., & Kawaguchi, T. (2026). The Impact of Tumor Immune Microenvironment in EGFR-Mutant Non-Small Cell Lung Cancer on the Efficacy of Osimertinib. Clinical Lung Cancer, 27(9), 1-10. https://doi.org/10.1016/j.cllc.2026.09.003

Vancouver

Mizutani M, Matsumoto Y, Ohe C, Sugimoto A, Nagamine H, Tani Y, et al. The Impact of Tumor Immune Microenvironment in EGFR-Mutant Non-Small Cell Lung Cancer on the Efficacy of Osimertinib. Clinical Lung Cancer. 2026;27(9):1-10. doi:10.1016/j.cllc.2026.09.003

BibTeX
@article{Mizutani2026,
  author = {Mizutani, Megumi and Matsumoto, Yoshiya and Ohe, Chisato and Sugimoto, Akira and Nagamine, Hiroaki and Tani, Yoko and Oka, Takako and Kaneda, Hiroyasu and Yamada, Kazuhiro and Watanabe, Tetsuya and Asai, Kazuhisa and Kimura, Tatsuo and Shiohara, Masanori and Kohashi, Kenichi and Kawaguchi, Tomoya},
  title = {The Impact of Tumor Immune Microenvironment in EGFR-Mutant Non-Small Cell Lung Cancer on the Efficacy of Osimertinib},
  journal = {Clinical Lung Cancer},
  year = {2026},
  volume = {27},
  number = {9},
  pages = {1--10},
  doi = {10.1016/j.cllc.2026.09.003}
}
Kostenlos starten →